The CCA's Board of Directors is comprised of highly capable, dedicated individuals with backgrounds in business, education, non-profit management, health care, cancer research, law and finance. In addition to their professional expertise, each board member has in some way been touched by colorectal cancer. Having a personal understanding of colorectal cancer and its impacts deepens their commitment to helping others affected by the disease — and to one day finding a cure.
Kevin Lewis, Co-Founder and Board Chairperson
A carrier of the HNPCC (hereditary non-polyposis colon cancer) gene, Mr. Lewis has had several family members who have died or suffered from colon cancer. He follows an extensive prevention regime designed to reduce his probability of developing a malignant tumor. He supports the National Cancer Institute by serving as a Patient Advocate on several programs. Mr. Lewis is a Principal and Partner at PwC, providing strategic operations expertise to technology-based clients. He has an MBA from Harvard Business School and an engineering degree from the University of Pennsylvania. His extensive corporate experience includes Raytheon, Teradyne, AMD, Boston Scientific Corporation, Schering Plough, IBM, and Alcatel Lucent, as well as Infolibria, an Internet startup company.
Michael Zahaby, Treasurer
Mr. Zahaby is the Chief Credit Officer and Managing Director of CapitalSpring Finance Company, a specialty finance company. Michael was a caregiver to his wife of 27 years in her two-year fight against colon cancer. He received a bachelor’s degree in Finance from Ohio State University’s Fisher School of Business, and an MBA from Thunderbird School of Global Management. He previously served on the board of the Southeast Pennsylvania United Way and chaired many of the board’s committees and sub-committees on funds allocation and children’s issues. Prior to CapitalSpring, Michael was a senior officer of Amalgamated Bank of New York; Morgan Stanley CFS, Inc., Merrill Lynch BFS, and Wachovia Bank, a successor to CoreStates Bank. He intends to dedicate his efforts to raising awareness of colon cancer in memory of his late wife, Sharon.
Johanna C. Bendell, M.D., Board Member
Dr. Bendell is the Director of GI Cancer Research; Associate Director, Drug Development, Sarah Cannon Research Institute. She is board certified in internal medicine and medical oncology and received her undergraduate and medical degrees from the University of Chicago. She completed her internship and residency in the Department of Internal Medicine at Brigham and Women’s Hospital in Boston, MA, as well as a fellowship in adult oncology at Boston’s Dana-Farber Cancer Institute. After finishing her training, she served as assistant of medicine at Massachusetts General Hospital and instructor in medicine at Harvard Medical School. She then was an assistant professor at Duke University specializing in gastrointestinal cancers and phase I research prior to joining Sarah Cannon Research Institute in 2008. At Sarah Cannon Research Institute Dr. Bendell leads GI Oncology research, where she designs the trial menu across all GI tumor types for the Sarah Cannon research network. She also focuses on early drug development of primarily targeted agents. Dr. Bendell has published in multiple journals including JCO, Cancer and The Lancet.
John Daly, MD, FACS, FRCS (G), FRCS (I), Board Member
Dr. Daly is the Dean Emeritus and the Donahoo Professor of Surgery at the Temple University School of Medicine and is internationally known as a surgeon, researcher, author and academician. During his career, Dr. Daly has been in leadership positions in a variety of organizations including the American Board of Colon and Rectal Surgery, the American Cancer Society and the American Surgical Society. Dr. Daly has been the recipient of numerous honors and awards for teaching, research and practice including the Sam E. Roberts Nutrition Foundation Medal of the University of Kansas (1981) and the Elliot Hochstein Medical Student Teaching Award of Cornell University (1995). He has also been included on many "best" lists such as Best Doctors in Philadelphia, Best Doctors in America and Top Cancer Doctors in New York. He is an active research investigator with over 15 years and $20 million of NIH funding. Dr. Daly was recently elected Vice President of the American College of Surgeons.
Joseph A. Frick, Board Member
Joseph A. Frick is Vice Chairman and Managing Partner based in the Philadelphia office. Prior to joining Diversified, Mr. Frick served as President & CEO of Independence Blue Cross and is currently a Vice Chair of the Independence Blue Cross Board of Directors. Prior to becoming CEO in 2005, Mr. Frick served as Independence Blue Cross’s Senior Vice President of Human Resources and Administration since 1997. In this capacity, he was responsible for corporate planning and business development, human resources, and administrative services. As CEO, Mr. Frick spearheaded the creation of IBC 2010, a long-term strategic plan for the company. He formed a new senior leadership team and launched key initiatives to achieve the company’s goals. Under Mr. Frick’s leadership, IBC enhanced its standing as a trusted and respected corporate leader in the Philadelphia community
Before joining Independence Blue Cross, Mr. Frick was Vice President of Human Resources at Philadelphia Newspapers, Inc. (PNI), which published The Philadelphia Inquirer and the Philadelphia Daily News. He joined PNI in 1987 as Personnel Development Director, responsible for employee relations, training, and development.
Michael Retsky, PhD., Board Member
Known for innovative research in the field of breast cancer, Dr. Retsky was Lecturer in Surgery at Harvard Medical School on Judah Folkman's staff for 12 years, until Dr. Folkman’s untimely death in 2008. Dr. Retsky is currently a Visiting Scientist at Harvard School of Public Health. His research field is computer simulation of cancer and angiogenesis. Dr. Retsky is an 18-year survivor of stage III colon cancer, and he designed his own long-term, low-dose chemotherapy regimen, now known as metronomic chemotherapy. In 2013, Dr. Retsky authored a study on reduction of breast cancer relapses in the peer-reviewed medical journal Current Medicinal Chemistry. He received a PhD in physics from the University of Chicago.
Jerry L. Tolk, Board Member
Mr. Tolk is a Senior Vice President and Regional Practice Leader for Edelman, the world’s largest health communications agency. In this role, Jerry works with a diverse cadre of healthcare, non-profit and NGO organizations across a broad range of marketing initiatives to motivate behavioral change and build engaged communities among patient, partner and clinical stakeholder groups. During his extensive career in health, first in the US Army, and later in a series of increasingly senior positions at the world’s leading PR and marketing agencies, Mr. Tolk has focused on creating novel health solutions through partnerships between organizations with mutual social and business interests. Mr. Tolk received his medical training at the US Army Medical College and studied graduate-level public relations strategy at NYU. When not traveling to speak of the AMA, PRSA and the request of healthcare organizations on topics of health engagement and strategic philanthropy, Mr. Tolk competes in triathlons to raise awareness and funding for disease research and patient programs.
Carmen Marc Valvo, Board Member
Fashion Designer Carmen Marc Valvo has used his designs as a platform to raise awareness about colon cancer all over the United States. Carmen is an Entertainment Industry Foundation (EIF) Ambassador and has appeared in a PSA with Vanessa Williams for the National Colorectal Cancer Research Alliance (NCCRA). As a colon cancer survivor, Carmen Marc Valvo has been working with Katie Couric since 2004 when she partnered with the organizers of New York Fashion Week. His efforts, on behalf of the organization, were honored at a gala in 2006 where Carmen received the first ever Advocate Award from the foundation. Since then Carmen has been honored by numerous organizations including Gilda’s Club World Wide, The National Coalition for Cancer Survivorship, The American Cancer Society, and The Colon Cancer Alliance. He has appeared on the covers of AARP and Coping with Cancer magazines, NBC Today Show, CBS Early Show, USA Today and countless other national and local media outlets to make colorectal cancer fashionable to talk about. His recent book: “Dressed to Perfection, The Art of Dressing for your Red Carpet Moments” (Rizzoli 2011) benefits colon cancer research.
For more information about the CCA Board, please contact:
The CCA's Medical Scientific Advisory Board advises the organization on new treatments, medications, research and other key issues related to this disease. The committee members volunteer their time and expertise to the CCA, ensuring that the information provided by the association is accurate and ethical.
Medical Scientific Advisory Committee Members:
Colon Cancer Survivor
Michael Choti, MD
Johns Hopkins University
James W. Fleshman, MD
Chief of Surgery
Co-Director of GI Center, Clinical Operations
Baylor University Medical Center
Kathleen Gamblin, RN, BSN, OCN
National Coalition of Oncology Nurse Navigators
Axel Grothey, MD
Amy Halverson, MD
Robert H. Lurie Comprehensive Cancer Center
Michael D. Kreines, MD, FACP, FACG
University of Cincinnati
John L. Marshall, MD
Ruesch Center for the Cure of Gastrointestinal Cancer
Lombardi Comprehensive Cancer Center
American College of Radiology
Jose Mendoza Silveiras, MD, PhD
Colon Cancer Survivor
Jeffrey A. Meyerhardt, MD, MPH
Dana-Farber Cancer Institute
Edith Mitchell, MD
Clinical Professor of Medicine and Medical Oncology
Jefferson Medical College of Thomas Jefferson University
Mark Pochapin, MD
Director, Division of Gastroenterology
Sholtz-Leeds Professor of Gastroenterology
NYU Langone Medical Center
Laura Porter, MD
Colon Cancer Survivor
Vetta L. Sanders Thompson, PhD
David Woo, PhD